Our Vaccines
Science
Vaxxilon was founded to develop synthetic carbohydrate vaccines. These vaccines are comprised of oligosaccharides (small fragments of naturally occurring carbohydrates) and the novel immune stimulator, alpha galactosylceramide. Two fundamental insights are the basis of this science:
Vaccine component
Advantages
ANTIGEN: Small, synthesized carbohydrate fragments which are the vaccine antigens can induce equivalent immunological response and memory. They replicate the natural structure of bacterial capsular polysaccharides.
Synthetic antigens are faster and less expensive to discover, develop, and manufacture. They could allow for lower doses, lead to protein sparing, and enable higher valency vaccines.
CARRIER: α-galactosylceramide (α-GSL) can replace carrier proteins and adjuvants used in currently available conjugate vaccines.
Fully synthetic vaccines which include a synthetic antigen and α-GSL are stable at room temperature. They could reduce the need for cumbersome cold chain distribution. The immunological mechanism of action may reduce the number of booster shots or allow for non-injectable administrations, easing the burden on the patients, parents, and health care providers around the world.
Pipeline
Through the rationale design of synthetic carbohydrate vaccines, Vaxxilon aims to improve existing vaccines and create new ones faster and less expensively with benefits to patients, parents, and health care providers around the world. We are advancing several vaccine candidates and considering new projects to initiate.
| Bacteria | Serotype | Vaccine Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|
| Streptococcus pneumoniae | 3 | Semi-synthetic |
.
|
||||
| Haemophilus influenzae type B | n/a | Semi-synthetic |
.
|
||||
| Streptococcus pneumoniae | multiple, undisclosed | Semi-synthetic |
.
|
||||
| Streptococcus pneumoniae | not disclosed | Fully-synthetic |
.
|
||||
| Klebsiella pneumoniae | multiple | Semi-synthetic |
.
|
||||
| 2 additional targets | undisclosed |
.
|
|||||
Publications
Basel Area
Vaxxilon AG
Christoph Merian-Ring 11,
4153 Reinach, Switzerland
Vaxxilon AG
Christoph Merian-Ring 11,
4153 Reinach, Switzerland
Berlin Area (Adlershof)
Vaxxilon Deutschland GmbH
Magnusstraße 11,
12489 Berlin, Germany
Vaxxilon Deutschland GmbH
Magnusstraße 11,
12489 Berlin, Germany
Copyright 2019 © Vaxxilon AG